CHARLES WYKOFF to United States
This is a "connection" page, showing publications CHARLES WYKOFF has written about United States.
Connection Strength
0.248
-
Syfovre Approval for Geographic Atrophy. JAMA Ophthalmol. 2024 Jul 01; 142(7):685-686.
Score: 0.079
-
Home Monitoring of Age-Related Macular Degeneration: Utility of the ForeseeHome Device for Detection of Neovascularization. Ophthalmol Retina. 2021 04; 5(4):348-356.
Score: 0.061
-
Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices. JAMA Ophthalmol. 2024 Aug 01; 142(8):716-721.
Score: 0.020
-
One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS? Registry. Ophthalmology. 2023 09; 130(9):937-946.
Score: 0.018
-
INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PHARMACEUTICAL UTILIZATION AND FINANCIAL IMPACT IN A VALUE-BASED CARE PROGRAM. Retina. 2023 03 01; 43(3):506-513.
Score: 0.018
-
Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records. Ophthalmology. 2020 09; 127(9):1179-1188.
Score: 0.015
-
Real-World Trends in Intravitreal Injection Practices among American Retina Specialists. Ophthalmol Retina. 2019 08; 3(8):656-662.
Score: 0.014
-
Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial. Ophthalmology. 2017 02; 124(2):215-223.
Score: 0.012
-
Regulatory Factors Influencing Usage of Retinal Pharmaceuticals: A Look Both Home and Abroad. Am J Ophthalmol. 2016 09; 169:xiv-xvi.
Score: 0.011